Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal
Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
